Cav1-KO Mouse
一般名
Cav1-KO
製品ID
S-KO-01349
背景情報
C57BL/6NCya
系統ID
KOCMP-12389-Cav1-B6N-VA
状況
このマウス系統を論文で使用する場合は、「Cav1-KO Mouse（カタログ番号S-KO-01349）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Cav1-KO
系統ID
KOCMP-12389-Cav1-B6N-VA
遺伝子名
製品ID
S-KO-01349
遺伝子別名
Cav, Cav-1
遺伝子別名
C57BL/6NCya
NCBI ID
修正
Conventional knockout
染色体
Chr 6
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000007799
NCBIトランスクリプトID
NM_007616
ターゲット領域
Exon 2
有効領域の大きさ
~0.2 kb
遺伝子研究の概要
Cav1, encoding caveolin-1, is a major protein of plasma membrane microdomains called caveolae [5]. It is involved in several signaling pathways, such as the PI3K-Akt, MAPK, and ErbB signal pathways [3]. Caveolin-1 also participates in the regulation of cell senescence, and is located at the adipocyte lipid droplet [5,6]. Genetic models are valuable for studying Cav1's role in various biological processes and diseases.
CAV1 polymorphisms like rs1049334, rs1049337, rs7804372 may be potential risk factors in urinary cancer, with rs1049334 increasing the risk and rs1049337 and rs7804372 potentially acting as protectors [1]. In breast cancer, rs3807987 and rs7804372 polymorphisms are associated with risk changes [2]. CAV1 is up-regulated in prostate cancer and its high expression is related to poor prognosis [3]. In esophageal cancer, its down-regulation is associated with higher tumor mutation burden and better response to immunotherapy [7]. In chronic allograft dysfunction, CAV1 promotes epithelial-to-mesenchymal transition and chronic renal allograft interstitial fibrosis through the ferroptosis pathway [4]. Biallelic CAV1 null variants lead to congenital generalized lipodystrophy with achalasia [5]. Celastrol can down-regulate CAV1 to attenuate the pro-tumorigenic effects of senescent cells [6]. In atrial fibrillation, CAV1 is critical for MG53 regulation of TGF-β1 signaling pathway-induced atrial fibrosis [8]. CAV1 is a prognostic predictor for patients with idiopathic pulmonary fibrosis and lung cancer [9].
In conclusion, Cav1 is crucial in multiple biological processes and diseases. Studies on Cav1 using gene-based models have revealed its significant roles in cancer, lipodystrophy, chronic allograft dysfunction, and other conditions, providing insights into disease mechanisms and potential therapeutic targets.
References:
1. Fan, Song, Meng, Jialin, Zhang, Li, Zhang, Xiansheng, Liang, Chaozhao. 2018. CAV1 polymorphisms rs1049334, rs1049337, rs7804372 might be the potential risk in tumorigenicity of urinary cancer: A systematic review and meta-analysis. In Pathology, research and practice, 215, 151-158. doi:10.1016/j.prp.2018.11.009. https://pubmed.ncbi.nlm.nih.gov/30463805/
2. Yan, Cunye, Sun, Chenyu, Ding, Xiuxiu, Chen, Ying, Wang, Benzhong. 2019. Association of CAV1 polymorphisms with the risks of breast cancer: A systematic review and meta-analysis. In Pathology, research and practice, 215, 152518. doi:10.1016/j.prp.2019.152518. https://pubmed.ncbi.nlm.nih.gov/31303379/
3. Guo, Liuxiong, Liu, Yixuan, Yang, Tao, Liu, Bin, Cai, Jianhui. . CAV1 and KRT5 are potential targets for prostate cancer. In Medicine, 102, e36473. doi:10.1097/MD.0000000000036473. https://pubmed.ncbi.nlm.nih.gov/38065913/
4. Han, Qianguang, Ni, Bin, Bao, Wei, Ju, Xiaobing, Tan, Ruoyun. 2025. CAV1 promotes epithelial-to-mesenchymal transition (EMT) and chronic renal allograft interstitial fibrosis by activating the ferroptosis pathway. In Frontiers in immunology, 16, 1523855. doi:10.3389/fimmu.2025.1523855. https://pubmed.ncbi.nlm.nih.gov/40013149/
5. Karhan, Asuman Nur, Zammouri, Jamila, Auclair, Martine, Jéru, Isabelle, Vigouroux, Corinne. 2021. Biallelic CAV1 null variants induce congenital generalized lipodystrophy with achalasia. In European journal of endocrinology, 185, 841-854. doi:10.1530/EJE-21-0915. https://pubmed.ncbi.nlm.nih.gov/34643546/
6. Zhang, Shuo, Zhu, Neng, Shi, Ya-Ning, Li, Hong-Fang, Qin, Li. 2024. Celastrol mediates CAV1 to attenuate pro-tumorigenic effects of senescent cells. In Phytomedicine : international journal of phytotherapy and phytopharmacology, 129, 155614. doi:10.1016/j.phymed.2024.155614. https://pubmed.ncbi.nlm.nih.gov/38692078/
7. Zhang, Runan, Wang, Haizhou, Xiao, Jun, Huang, Tizheng, Zhao, Qiu. 2022. CAV1 Impacts the Tumor Immune Microenvironment and Has Potential Value of Predicting Response to Immunotherapy in Esophageal Cancer. In DNA and cell biology, 42, 27-42. doi:10.1089/dna.2022.0025. https://pubmed.ncbi.nlm.nih.gov/36638349/
8. Zhang, Meixia, Wang, Hechuan, Wang, Xiaowen, Lu, Kai, Xiao, Hua. 2020. MG53/CAV1 regulates transforming growth factor-β1 signaling-induced atrial fibrosis in atrial fibrillation. In Cell cycle (Georgetown, Tex.), 19, 2734-2744. doi:10.1080/15384101.2020.1827183. https://pubmed.ncbi.nlm.nih.gov/33000676/
9. Yin, Dongdong, Qiu, Jiayang, Hu, Suxia, Wang, Shun, Lu, Jun. . CAV1 is a prognostic predictor for patients with idiopathic pulmonary fibrosis and lung cancer. In Journal of biosciences, 47, . doi:. https://pubmed.ncbi.nlm.nih.gov/35092415/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。